Lange Justus Johann, Senniksen Malte Bøgh, Wyttenbach Nicole, Page Susanne, Bateman Lorraine M, O'Dwyer Patrick J, Saal Wiebke, Kuentz Martin, Griffin Brendan T
School of Pharmacy, University College Cork, College Road, Cork County, T12 R229 Cork , Ireland.
Pharmaceutical R&D, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
Mol Pharm. 2025 Apr 7;22(4):1958-1972. doi: 10.1021/acs.molpharmaceut.4c01140. Epub 2025 Mar 11.
More than a decade since its introduction, the polymeric excipient Soluplus continues to receive considerable attention for its application in the development of amorphous solid dispersions (ASDs) and its utility as a solubilizer for drugs exhibiting solubility limited absorption. While it is well-recognized that Soluplus forms micelles, the impact of its lower critical solution temperature of approximately 40 °C remains an underexplored aspect. This study investigated the phase behavior of Soluplus in fasted-state simulated intestinal fluid (FaSSIF-V1). It was demonstrated that Soluplus forms a dispersed polymer-rich coacervate phase, which coexists with Soluplus micelles at 37 °C. This behavior was confirmed by cloud point measurements, visually discernible phases after centrifugation, as well as multi-angle dynamic light scattering (MADLS) measurements, and quantitative H-nuclear magnetic resonance (NMR) spectroscopy of Soluplus concentrations in the supernatant pre- and post-centrifugation. The practical relevance of these findings was contextualized by solvent shift experiments and dissolution testing of spray-dried ASD. The results demonstrated that the poorly water-soluble drug RO6897779 resided in a polymer-rich coacervate phase and was spun down during centrifugation, which resulted in an amorphous pellet exhibiting the characteristics of a viscous liquid. The entrapment of the drug within the polymer-rich phase was further analyzed by temperature- and time-dependent MADLS experiments. The findings of this study are of particular relevance for a mechanistic understanding, relevant to comprehending in vitro-in vivo relationships of Soluplus-based ASDs. Low sampled drug concentrations in FaSSIF-V1 at 37 °C may originate not only from limited drug release and precipitation but also from the formation of a drug-containing, polymer-rich Soluplus phase. Therefore, a liquid-liquid phase separation occurring from Soluplus-based formulations in a biorelevant medium can be excipient-driven, which is different from the common perception that phase separation in the solution state is triggered primarily by high drug concentrations exceeding their amorphous solubility.
聚合物辅料Soluplus推出已有十多年,因其在无定形固体分散体(ASD)开发中的应用以及作为具有溶解度限制吸收的药物的增溶剂的效用,继续受到广泛关注。虽然人们普遍认识到Soluplus会形成胶束,但其约40°C的较低临界溶液温度的影响仍是一个未被充分探索的方面。本研究调查了Soluplus在禁食状态模拟肠液(FaSSIF-V1)中的相行为。结果表明,Soluplus形成了富含聚合物的分散凝聚相,该相在37°C时与Soluplus胶束共存。通过浊点测量、离心后肉眼可辨别的相以及多角度动态光散射(MADLS)测量,以及离心前后上清液中Soluplus浓度的定量氢核磁共振(NMR)光谱,证实了这种行为。通过溶剂转移实验和喷雾干燥ASD的溶出试验,将这些发现的实际相关性进行了背景化。结果表明,难溶性药物RO6897779存在于富含聚合物的凝聚相中,并在离心过程中被沉淀下来,形成了具有粘性液体特征的无定形颗粒。通过温度和时间依赖性MADLS实验进一步分析了药物在富含聚合物相中的包封情况。本研究的结果对于理解基于Soluplus的ASD的体外-体内关系的机制具有特别重要的意义。在37°C的FaSSIF-V1中药物浓度较低,可能不仅源于药物释放和沉淀受限,还源于形成了含药物的、富含聚合物的Soluplus相。因此,基于Soluplus的制剂在生物相关介质中发生的液-液相分离可能是由辅料驱动的,这与通常认为溶液状态下的相分离主要由超过其无定形溶解度的高药物浓度触发的观点不同。